Drugs / Lutetium Lu 177-PSMA-617
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03805594 | May 2019 → Jan 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05113537 | Jul 2022 → May 2026 overdue | castration-resistant prostate carcinoma, prostate adenocarcinoma | Vadim S Koshkin | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium Lu 177-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805594 ↗ |
| Action | Deplete | “Its radiation component destroys the tumor cell.” NCT03805594 ↗ |
| Modality | Other / unclassified | “Lu-PSMA radioligand therapy (RLT)” NCT03805594 ↗ |
| Route | Intravenous | “lutetium Lu 177-PSMA-617 intravenously (IV) over 20-30 minutes” NCT03805594 ↗ |